工程化ZPI突变体作为血友病治疗的新型拮抗剂
本研究通过引入两个丙氨酸突变(Y387A和K239A)构建了ZPI-2A突变体,使其失去抑制FXa/FXIa的活性并增强与PZ的结合亲和力。体外和血浆实验表明,ZPI-2A能剂量依赖性地逆转ZPI/PZ的抗凝血功能,三倍摩尔过量即可完全逆转凝血酶生成抑制,且所需剂量显著低于PZ抗体,有望成为血友病预防性治疗药物。
要点
- ZPI-2A突变体结合PZ的亲和力比野生型ZPI或PZ抗体高20倍以上。
- ZPI-2A以约三倍摩尔过量即可有效中和ZPI/PZ的抗FXa活性。
- ZPI-2A在血友病血浆中剂量依赖性地逆转ZPI/PZ对凝血酶生成的抑制。
核心结论
- ZPI-2A是ZPI/PZ抗凝血功能的有效拮抗剂,能以显著低于PZ抗体的剂量完全阻断血浆水平ZPI/PZ的抗FXa活性,有望成为血友病的预防性治疗药物。
研究设计与样本
- 通过定点突变在人ZPI中引入Y387A(反应环P1残基,灭活FXa/FXIa抑制功能)和K239A(PZ结合界面残基,增强与PZ亲和力),表达纯化后通过体外和血浆实验进行表征。
主要发现
- ZPI-2A结合PZ的亲和力比野生型ZPI或PZ抗体高20倍以上。
- 在FXa抑制实验中,无论FXa是否与FVa结合于凝血酶原酶复合物,ZPI-2A均以约三倍摩尔过量有效中和ZPI/PZ的抗FXa活性。
- 在纯化系统及正常/血友病血浆的凝血酶生成实验中,ZPI-2A剂量依赖性地逆转ZPI/PZ活性,三倍摩尔过量足以完全逆转ZPI/PZ对凝血酶生成的抑制。
临床怎么用
- ZPI-2A可作为血友病预防性治疗的候选药物,通过拮抗ZPI/PZ抗凝血功能恢复止血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Protein Z-dependent protease inhibitor (ZPI), is an important anticoagulant protein in plasma that functions in complex with its cofactor, protein Z (PZ) to rapidly inhibit activated factor X (FXa) on a procoagulant membrane surface. Recent studies suggest that the ZPI-PZ anticoagulant complex is a promising target for restoring hemostasis in hemophilia (Girard, et al, J Thromb Haemost, 2019, 17, 149-156). OBJECTIVE: Engineering a ZPI mutant as a novel antagonist of ZPI anticoagulant function. METHODS: We engineered two alanine mutations in human ZPI, one in the reactive loop P1 Y387 residue to inactivate the FXa/FXIa inhibitory function, and the second in the K239 binding interface residue to enhance the affinity of the inactive ZPI for PZ. The mutant was expressed, purified, and characterized by in vitro and plasma assays. RESULTS: The mutant, Y387A/K239A (ZPI-2A), bound PZ >20-fold tighter than WT ZPI or a PZ antibody (PZAb). FXa inhibition assays showed that ZPI-2A effectively neutralized ZPI/PZ anti-FXa activity with a ~three-fold molar excess over wild type ZPI (WT ZPI) whether FXa was bound to FVa in prothrombinase or unbound. Thrombin generation assays in a purified system or in normal/hemophilia plasmas showed that ZPI/PZ activity was reversed by ZPI-2A in a dose-dependent manner, with a three-fold molar excess sufficient to fully reverse ZPI/PZ inhibition of thrombin generation. CONCLUSIONS: ZPI-2A is a potent antagonist of ZPI/PZ anticoagulant function, capable of fully blocking the anti-FXa activity of plasma levels of ZPI/PZ at significantly lower doses than a PZAb and thus a promising prophylactic agent for treating hemophilia.
引用
- Huang X. Engineering a protein Z-dependent protease inhibitor (ZPI) mutant as a novel antagonist of ZPI anticoagulant function for hemophilia treatment. J Thromb Haemost. 2019. PMID: 31423718. doi:10.1111/jth.14610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。